Condition: Advanced Solid Tumor · Non-Small Cell Lung Cancer · Colorectal Neoplasms · Sponsor: Blueprint Medicines Corporation
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.
This description comes directly from the study's public registry record.
Blueprint Medicines · 1-888-258-7768 · medinfo@blueprintmedicines.com
Always discuss trial participation with your own doctor first.
| Next Oncology Virginia Cancer Specialist | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07629960